use
rna
interfer
rnai
spread
rapidli
nearli
everi
aspect
biomed
research
gene
silenc
capabl
rnai
use
studi
individu
gene
biolog
function
role
biochem
pathway
howev
efficaci
rnai
depend
upon
effici
deliveri
intermedi
rnai
short
interf
rna
sirna
short
hairpin
rna
shrna
oligonucleotid
deliveri
challeng
even
greater
aim
inhibit
express
target
gene
anim
model
although
vivo
deliveri
sirna
complic
challeng
recent
result
encourag
review
latest
develop
vivo
deliveri
sirna
crucial
issu
relat
effort
address
review
rnai
rapidli
adopt
discoveri
valid
gene
function
use
sequencespecif
short
interf
rna
sirna
origin
identifi
doublestrand
rna
fragment
gener
cellular
enzym
call
dicer
sirna
intermedi
found
form
rnainduc
silenc
complex
risc
cellular
protein
select
degrad
complementari
singlestrand
target
rna
sequenc
specif
manner
sirna
use
character
gene
function
also
rapidli
adopt
ht
potenti
therapeut
target
pharmaceut
research
laboratori
consequ
grow
success
use
sirna
research
tool
vitro
vivo
emerg
interest
use
sirna
therapeut
agent
howev
rel
small
number
report
vivo
sirna
studi
indic
lack
effect
vivo
deliveri
method
especi
achiev
rnaimedi
downregul
specif
gene
target
anim
diseas
model
review
address
problem
vivo
sirna
deliveri
discuss
approach
overcom
problem
function
target
gene
valid
inhibit
target
protein
examin
induc
phenotyp
chang
variou
mean
includ
biochem
pharmacolog
histolog
assay
convent
target
valid
time
consum
process
last
year
time
request
screen
smallmolecul
inhibitor
target
protein
gener
gene
knockout
anim
potent
specif
inhibitor
gene
express
sirna
rapidli
adopt
prefer
tool
function
genom
research
sirna
oligo
typic
use
inhibit
individu
gene
although
target
multipl
gene
group
gene
possibl
use
combin
multipl
sirna
sequenc
success
sirna
vitro
led
grow
interest
vivo
applic
sirna
applic
eventu
provid
valid
target
convent
therapeut
modal
small
molecul
monoclon
antibodi
inhibitor
well
valid
sirna
drug
lead
vivo
sirna
target
valid
approach
greatli
shorten
process
target
valid
take
day
select
potent
sirna
inhibitor
virtual
target
gene
compar
month
year
screen
smallmolecul
inhibitor
cancer
research
exampl
tumorigenesi
process
recogn
result
abnorm
overexpress
oncogen
growth
factor
mutant
tumor
suppressor
even
underexpress
protein
also
play
crucial
role
effort
identifi
valid
target
develop
cancer
therapeut
mainli
focus
protein
overexpress
tumor
tissu
might
promot
tumorigenesi
among
wellknown
oncogen
growth
factor
vascular
endotheli
growth
factor
vegf
epiderm
growth
factor
egf
fibroblast
growth
factor
fgf
receptor
repres
wide
recogn
target
origin
took
year
valid
recent
studi
sirnamedi
downregul
proangiogenesi
gene
vegf
vegf
receptor
clinic
relev
xenograft
tumor
model
result
signific
antitumor
efficaci
use
technolog
function
two
target
rapidli
revalid
week
exampl
demonstr
power
vivo
target
valid
sirna
inhibitor
case
role
proangiogen
factor
valid
also
sirna
inhibitor
valid
potenti
anticanc
drug
deliv
sirna
vivo
anim
tissu
complic
involv
use
physic
chemic
biolog
approach
case
combin
main
goal
vivo
deliveri
activ
sirna
oligo
target
cell
stabil
sirna
oligo
extracellular
intracellular
environ
system
administr
challeng
issu
figur
first
hurdl
size
doublestrand
sirna
oligo
oligo
rel
small
thu
rapidli
excret
urin
administr
blood
stream
even
sirna
molecul
remain
stabl
chemic
modif
second
doublestrand
sirna
oligo
rel
unstabl
serum
environ
degrad
rnase
activ
within
short
period
time
third
sirna
administ
system
nonspecif
distribut
oligo
throughout
bodi
significantli
degreas
local
concentr
diseas
occur
addit
sirna
oligo
need
overcom
blood
vessel
endotheli
wall
multipl
tissu
barrier
reach
target
cell
final
sirna
reach
target
cell
cellular
uptak
oligo
intracellular
rnai
activ
requir
effici
endocytosi
intact
doublestrand
oligo
respect
increas
stabil
extracellular
intracellular
environ
sirna
oligo
chemic
modifi
varieti
method
includ
chang
oligo
backbon
replac
individu
nucleotid
nucleotid
analogu
addit
conjug
oligo
chemic
modifi
sirna
demonstr
signific
serum
resist
higher
stabil
solv
problem
urin
excret
target
deliveri
therefor
deliveri
system
capabl
protect
sirna
oligo
urin
excret
rnase
degrad
transport
sirna
oligo
physic
barrier
target
tissu
enhanc
cellular
uptak
sirna
key
success
vivo
sirna
applic
access
differ
tissu
type
variou
deliveri
rout
varieti
pharmacolog
requir
make
imposs
univers
vivo
deliveri
system
suitabl
everi
scenario
sirna
deliveri
term
vivo
deliveri
vehicl
sirna
nonvir
carrier
major
type
investig
far
although
physic
viral
deliveri
approach
also
effect
rout
vivo
deliveri
commonli
categor
local
system
deliveri
vehicl
deliveri
rout
effici
target
valid
anim
might
use
deliveri
sirna
therapeut
human
figur
therefor
vivo
sirna
deliveri
carrier
method
also
classifi
clinic
viabl
nonclin
viabl
accord
suitabl
human
challeng
vivo
sirna
deliveri
vivo
applic
especi
system
deliveri
sirna
face
challeng
multipl
hurdl
extracellular
environ
variou
barrier
intracellular
uptak
address
issu
crucial
effici
vivo
deliveri
sirna
preclin
anim
model
drug
target
valid
potenti
therapeut
mani
nonvir
carrier
use
deliveri
dna
gene
therapi
adopt
sirna
deliveri
rnai
activ
cytoplasm
deliveri
sirna
rel
easier
deliveri
plasmid
viral
dna
nucleu
express
nonvir
sirna
deliveri
diseas
tissu
elicit
immun
respons
great
advantag
applic
drug
target
valid
also
allow
multipl
administr
sirna
crucial
sirna
therapeut
applic
cation
lipid
polym
two
major
class
nonvir
sirna
deliveri
carrier
posit
charg
form
complex
neg
charg
sirna
sirnacarri
complex
condens
tini
nanoparticl
nm
allow
effici
cellular
uptak
sirna
agent
endocytosi
process
mous
model
report
gene
silenc
downregul
tumor
necrosi
factor
express
achiev
intraperiton
ip
administr
sirnalipoplex
recent
studi
report
use
cation
deriv
cardiolipin
form
lipoplex
sirna
target
craf
oncogen
led
inhibit
tumor
growth
sequenc
specif
manner
anoth
studi
famili
highli
branch
histidinelysin
hk
peptid
found
effect
carrier
sirna
express
xenograft
significantli
inhibit
intratumor
inject
sirna
complex
hk
polym
anoth
recent
studi
demonstr
signific
inhibit
express
tumor
growth
ip
inject
sirna
formul
polyethylenimin
pei
studi
demonstr
cation
lipid
polym
enhanc
sirna
deliveri
vivo
system
rout
either
intraven
iv
ip
carrieradminist
sirna
agent
effici
knock
target
gene
achiev
antitumor
efficaci
contrast
direct
intratumor
inject
vegf
sirna
without
carrier
gener
signific
antitumor
efficaci
antivir
studi
iv
administr
sirna
specif
target
influenza
viru
rna
genom
complex
pei
abl
inhibit
influenza
viru
product
mice
ligandtarget
sirna
deliveri
system
develop
use
cation
liposom
complex
polym
complex
system
recent
success
use
ligandtarget
complex
deliv
therapeut
sirna
tumor
tissu
liver
tissu
suggest
target
system
deliveri
sirna
therapeut
promis
demonstr
effici
system
deliveri
sirna
reach
tumor
neovasculatur
tissu
tumor
model
ocular
neovasculatur
tissu
herp
simplex
viru
hsv
eye
infect
model
ligandtarget
nanoparticl
argglyasp
rgd
motif
peptid
ligand
specif
activ
integrin
receptor
marker
endothelium
tumor
cell
ligandtarget
nanoparticl
maintain
stabil
sirna
payload
target
tumor
neovasculatur
enhanc
cellular
uptak
sirna
target
mrna
result
antiangiogenesi
effect
observ
xenograft
tumor
model
ocular
neovascular
hsv
diseas
model
importantli
sirna
nanoparticl
deliveri
system
clinic
viabl
use
variou
applic
sirna
therapeut
report
sirna
trigger
offtarget
effect
activ
cellular
interferon
pathway
especi
deliv
cation
liposom
polym
transfect
reagent
issu
rais
concern
integr
target
valid
studi
safeti
select
potenti
sirna
therapeut
howev
major
alarm
result
obtain
vitro
studi
mani
studi
shown
sirna
inhibitor
highli
specif
vitro
vivo
recent
studi
use
system
deliveri
unmodifi
unformul
sirna
oligo
mice
reveal
lack
interferon
respons
two
recent
report
reveal
sirna
oligo
contain
motif
abl
induc
tolllik
receptormedi
interferon
respons
deliv
vivo
cation
lipid
polym
carrier
either
iv
ip
administr
contrast
neither
unformul
sirna
oligo
contain
motif
sirna
contain
motif
cation
carrier
abl
induc
interferon
respons
reason
motif
potenti
immunostimulatori
motif
elimin
sirna
oligo
cation
lipid
polym
carrier
go
use
choic
local
system
deliveri
depend
tissu
cell
type
target
exampl
skin
muscl
better
access
use
local
sirna
deliveri
wherea
lung
tumor
reach
effici
local
system
sirna
deliveri
increas
evid
sirna
effici
deliv
variou
tissu
type
use
differ
approach
figur
airway
deliveri
sirna
use
method
target
valid
therapeut
develop
relev
respiratori
system
variou
diseas
recent
studi
intranas
deliveri
dehydrogenas
gapdh
specif
sirna
mix
pulmonari
surfac
activ
materi
elastas
result
lower
gapdh
protein
level
lung
heart
kidney
day
day
administr
compar
scrambl
sirna
control
direct
deliveri
unformul
sirna
mous
airway
led
knockdown
heme
express
lung
intranas
administr
cation
liposomeformul
sirna
specif
target
influenza
viru
rna
genom
mous
lung
infect
influenza
viru
result
significantli
reduc
lung
viru
titer
infect
mice
protect
anim
lethal
challeng
howev
vivo
deliveri
sirna
cation
polym
carrier
pei
often
associ
sever
toxic
host
might
induc
nonspecif
interferon
respons
tolllik
receptor
pathway
discuss
therefor
pulmonari
sirna
deliveri
might
requir
formul
without
cation
carrier
recent
success
deliv
sirna
dglucos
water
solut
mous
monkey
lung
achiev
effect
knockdown
sever
acut
respiratori
syndrom
sar
coronaviru
rna
increas
number
clinic
protocol
approv
treat
eye
diseas
nucleic
acid
drug
antisens
oligonucleotid
rna
aptam
deliveri
nonformul
sirna
specif
vegf
subretin
space
mous
model
retin
neovascular
result
signific
reduct
angiogenesi
eye
importantli
studi
indic
chemic
protect
sirna
essenti
least
intravitr
compart
eye
contrast
antisens
oligonucleotid
rna
aptam
need
chemic
modif
applic
eye
use
murin
model
herpet
stromal
ketat
develop
herp
simplex
viru
corneal
infect
found
subconjunctiv
administr
sirna
target
sever
gene
vegf
pathway
significantli
inhibit
corneal
angiogenesi
diseas
symptom
subconjunctiv
deliveri
sirna
specif
transform
growth
factor
significantli
reduc
inflammatori
respons
matrix
deposit
woundinduc
mous
model
ocular
inflamm
evid
also
provid
clinic
viabl
mean
local
deliveri
sirna
gene
function
valid
variou
eye
diseas
model
local
deliveri
sirna
front
eye
subconjunctiv
back
eye
intravitr
highli
effici
silenc
target
gene
express
therefor
effect
administr
rout
target
valid
eye
diseas
howev
frequenc
time
interv
repeat
deliveri
might
limit
factor
deliveri
rout
especi
clinic
applic
sirna
therapeut
brain
tissu
foundat
central
nervou
system
cn
obvious
import
biolog
system
draw
interest
function
genom
research
therapeut
develop
recent
studi
show
infus
aqueou
solut
chemic
protect
sirna
oligonucleotid
directli
brain
abl
select
inhibit
gene
express
treatment
rat
aqueou
sirna
adrenerg
receptor
ar
day
birth
result
acut
decreas
level
ar
mrna
brainstem
sirna
inject
nonvir
infus
sirna
brain
provid
uniqu
approach
acceler
target
valid
neuropsychiatr
disord
involv
complex
interplay
gene
variou
brain
region
exampl
infus
sirna
specif
endogen
dopamin
transport
dat
gene
region
ventral
midbrain
far
distal
infus
site
result
signific
downregul
dat
mrna
protein
brain
elicit
tempor
hyperlocomotor
respons
similar
obtain
upon
infus
pharmacolog
select
dat
inhibitor
howev
difficulti
perform
surgic
implant
infus
pump
deliv
high
dose
sirna
limit
use
tool
function
genom
anoth
recent
studi
use
cation
formul
sirna
deliveri
brain
reveal
deliveri
effici
use
lipid
carrier
polym
carrier
electropor
physic
approach
use
introduc
dna
cell
process
electropor
electr
field
puls
induc
pore
electropor
cell
membran
allow
dna
molecul
enter
cell
recent
electropor
procedur
adopt
local
deliveri
sirna
one
studi
sirna
introduc
hippocampu
region
local
electropor
led
mark
reduct
express
level
mrna
protein
target
gene
glutam
receptor
cyclooxygenas
without
affect
express
level
protein
skeletalmuscl
tissu
access
local
sirna
administr
direct
inject
sirna
formul
cation
lipid
polym
consid
local
deliveri
although
applic
vivo
sirna
deliveri
diseas
model
mous
model
wide
use
vivo
sirna
deliveri
studi
sirna
deliv
mani
rout
base
diseas
type
target
tissuesth
efficaci
toxic
readout
sirna
inhibitor
preclin
model
provid
vital
inform
vivo
target
valid
inflamm
caus
inject
common
problem
recent
studi
nonformul
sirna
deliv
direct
inject
mous
muscl
follow
electropor
demonstr
signific
gene
silenc
last
day
electropor
method
also
appli
differ
studi
target
sever
report
gene
murin
skelet
muscl
local
hydrodynam
approach
suffici
volum
sirna
rapidli
inject
distal
vein
limb
transient
isol
tourniquet
blood
pressur
cuff
test
sirna
deliveri
muscl
anim
model
demonstr
knockdown
report
endogen
gene
intratumor
deliveri
sirna
attract
approach
function
valid
tumorigen
gene
observ
inhibit
tumor
growth
two
human
breast
cancer
xenograft
use
intratumor
deliveri
vegf
specif
sirna
report
atelocollagen
collagen
solubil
proteas
protect
sirna
digest
rnase
form
complex
sirna
addit
sirna
slowli
releas
atelocollagen
effici
transduc
cell
allow
longterm
target
gene
silenc
mous
xenograft
tumor
studi
administr
atelocollagenlucsirna
complex
intratumor
reduc
luciferas
express
observ
furthermor
intratumor
inject
atelocollagenvegfsirna
show
effici
inhibit
tumor
growth
orthotop
xenograft
model
human
nonseminomat
germ
cell
tumor
similar
result
observ
human
prostat
tumor
xenograft
use
sirna
deliveri
approach
therefor
atelocollagenbas
sirna
deliveri
method
could
reliabl
approach
achiev
maxim
inhibit
gene
function
vivo
basi
success
valid
group
novel
gene
role
tumorgenesi
use
intratumor
deliveri
formul
sirna
believ
intratumor
deliv
sirna
tumor
xenograft
use
platform
vivo
target
valid
system
administr
sirna
agent
attract
approach
drug
target
valid
therapeut
applic
hurdl
describ
figur
address
usual
purpos
system
administr
deliv
sirna
throughout
entir
bodi
reach
specif
diseas
tissu
two
tissu
type
particular
interest
mani
sirna
deliveri
effort
liver
tumor
first
publish
result
show
activ
sirna
mammal
involv
deliveri
sirna
mous
liver
use
hydrodynam
method
consist
rapid
inject
larg
volum
aqueou
solut
mous
tail
vein
creat
high
pressur
vascular
circul
lead
extens
deliveri
sirna
hepatocyt
procedur
allow
high
effici
sirna
uptak
potent
sirna
activ
hepatocyt
thu
use
tool
function
genom
studi
liver
howev
procedur
clinic
viabl
potenti
damag
liver
organ
therefor
limit
research
liver
function
metabol
liver
infecti
diseas
hepat
hepatocyt
specif
target
carrier
sirna
deliveri
liver
attract
approach
develop
sirna
therapeut
hepat
diseas
current
investig
one
step
toward
livertarget
deliveri
liver
deliveri
chemic
modifi
oligonucleotid
cholesterol
conjug
test
describ
recent
public
data
suggest
least
three
challeng
must
address
adequ
protect
serum
degrad
sirna
oligonucleotid
way
liver
protect
sirna
oligonucleotid
rapid
glomerulofiltr
kidney
urin
select
uptak
target
hepatocyt
addit
high
dose
use
cholesterolconjug
sirna
iv
deliveri
indic
widespread
distribut
rather
liver
target
recent
report
indic
lipidencapsul
sirna
target
hepat
b
viru
hbv
rna
abl
exert
potent
persist
antivir
activ
hbv
mous
model
iv
inject
although
conclus
report
chemic
modif
sirna
import
potenc
report
clarifi
whether
modif
crucial
lipidencapsul
appli
malign
tumor
grow
fast
spread
throughout
bodi
via
blood
lymphat
system
metastat
tumor
establish
distant
locat
usual
encapsul
thu
amen
system
deliveri
local
sirna
administr
method
discuss
meet
requir
function
genom
studi
act
primari
tumor
xenograft
model
form
basi
cancer
biolog
research
howev
system
deliveri
sirna
need
studi
relat
gene
function
also
sirnabas
cancer
therapeut
system
sirna
deliveri
impos
sever
requir
greater
hurdl
local
sirna
deliveri
requir
stabl
oligonucleotid
blood
local
environ
enter
target
cell
addit
sirna
need
pass
multipl
tissu
barrier
reach
target
cell
recent
studi
pancrea
xenograft
use
system
administr
sirna
without
protect
formul
studi
demonstr
signific
suppress
primari
tumor
growth
versu
control
sirna
associ
decreas
prolifer
index
tumor
cell
impair
angiogenesi
increas
apoptosi
treatment
sirna
complet
inhibit
metastasi
significantli
improv
surviv
without
appar
toxic
recent
studi
show
tumortarget
sirna
deliveri
achiev
use
rgd
peptid
liganddirect
nanoparticl
applic
antiangiogen
treatment
cancer
obtain
system
sirna
deliveri
review
elsewher
recent
studi
rgd
ligandtarget
nanoparticl
target
neovasculatur
ocular
neovascular
model
antiangiogenesi
efficaci
observ
ocular
neovascular
model
demonstr
approach
clinic
viabl
method
sirna
therapeut
addit
demonstr
sirna
oligo
specif
sever
gene
combin
nanoparticl
give
better
inhibit
diseas
patholog
target
sirna
deliveri
provid
uniqu
therapeut
approach
dualtarget
therapeut
recent
antibodymedi
deliveri
sirna
report
tumor
target
via
cellsurfac
receptor
sirna
cocktail
target
cmyc
vegf
complex
antibodyprotamin
abl
effici
deliv
cell
form
tumor
overexpress
surfac
protein
either
local
system
deliveri
achiev
antitumor
activ
antibodymedi
bind
artifici
tumor
cell
interest
proof
concept
might
limit
clinic
viabl
deliveri
current
vivo
sirna
deliveri
either
local
system
rout
mainli
serv
research
tool
function
genom
proof
principl
potenti
rnai
therapeut
tabl
therefor
examin
util
sirna
deliveri
method
vivo
requir
confirm
robust
target
valid
process
repeat
test
preclin
model
signific
advantag
sirna
rapid
differ
sirna
sequenc
match
gene
studi
particularli
use
drug
target
valid
moreov
develop
optim
sirna
deliveri
variou
type
anim
diseas
model
challeng
worthi
effort
acceler
novel
drug
discoveri
process
grow
knowledg
vivo
sirna
deliveri
potenti
therapeut
applic
sirna
agent
emerg
date
two
sirna
therapeut
protocol
test
phase
clinic
trial
treatment
ocular
neovascular
diseas
mani
late
stage
preclin
studi
variou
indic
ultim
effort
vivo
sirna
deliveri
translat
mani
clinic
viabl
administr
method
sirnabas
therapeut
treat
variou
cancer
viral
infect
autoimmun
cn
diseas
mous
nake
intranas
administr
apob
mous
stabil
cholsirna
iv
inject
mous
lipiodol
highvolum
portal
vein
inject
abbrevi
purinoceptor
apob
apolipoprotein
b
pb
phosphat
buffer
salin
dotap
dioleoyl
trimethylammonium
